You just read:

Merck Announces Results from C-SURFER Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease

News provided by

Merck Canada Inc.

Apr 24, 2015, 07:00 ET